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Synopsis
The past decade has seen a rapid development and increasing recognition of ANGPTL4 (angiopoietin-like 4) as a
remarkably multifaceted protein that is involved in many metabolic and non-metabolic conditions. ANGPTL4 has
been recognised as a central player in various aspects of energy homoeostasis, at least in part, via the inhibitory
interaction between the coiled-coil domain of ANGPTL4 and LPL (lipoprotein lipase). The fibrinogen-like domain of
ANGPTL4 interacts and activates specific integrins to facilitate wound healing, modulates vascular permeability,
and regulates ROS (reactive oxygen species) level to promote tumorigenesis. The present review summarizes these
landmark findings about ANGPTL4 and highlights several important implications for future clinical practice. Importantly,
these implications have also raised many questions that are in urgent need of further investigations, particularly the
transcription regulation of ANGPTL4 expression, and the post-translation cleavage and modifications of ANGPTL4.
The research findings over the past decade have laid the foundation for a better mechanistic understanding of the
new scientific discoveries on the diverse roles of ANGPTL4.
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INTRODUCTION
In 2000, three independent research groups simultaneously iden-
tified a new protein that was similar to members of the ANG
(angiopoietin) family. Kim et al. [1] identified the hepatic
fibrinogen/ANG-related protein while performing a degenerative
PCR screen for proteins homologous to the ANG family. During
a screen for novel target genes of the nuclear receptor PPARα
(peroxisome-proliferator-activated receptor α), Kersten et al. [2]
isolated a fasting-induced adipose factor from the liver. Simil-
arly, Yoon et al. [3] discovered a PPARγ /ANG-related protein as
a downstream target of PPARα and PPARγ during pre-adipocyte
differentiation. The HUGO Gene Nomenclature Committee has
now named the gene encoding this protein ANGPTL4 (ANG-like
4). Shortly after its discovery, the ANGPTL4 protein was classi-
fied as an adipokine due to its predominant expression in adipose
tissues and liver; thus, it was believed to be involved in lipid meta-
bolism. From intensive studies that have been carried out over the
past decade, increasing recognition of this protein as a remark-
ably dynamic entity that is involved in a myriad of physiological
and pathological conditions has occurred. The functions of this
protein extend far beyond what was previously predicted and now
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include energy homoeostasis, wound repair, tumorigenesis, an-
giogenesis and redox regulation. The present review summarizes
our current knowledge of ANGPTL4 and aims to identify other
prospective research areas that will eventually serve the ultimate
goals of applying new techniques in biomedicine and improving
human health.
STRUCTURE AND EXPRESSION
PATTERN OF ANGPTL4
The ANGPTL proteins belong to a superfamily of angiogenic-
regulating, secreted proteins that bear the highest similarity to
members of the ANG family. All members of the ANG-like
family (ANGPTL1–7) have been found in both humans and
mice, except for ANGPTL5, which is a human orthologue.
The human ANGPTL4 gene is well conserved among differ-
ent species and shares ∼77 % and 99 % amino acid sequence
similarity with mouse and chimpanzee respectively. The hu-
man ANGPTL4 gene is located on chromosome 19p13.3, has
seven exons and encodes a 406-amino-acid glycoprotein with
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a molecular mass of ∼45–65 kDa. Like other members of this
family, ANGPTL4 has a secretory signal peptide and contains
a predicted N-terminal coiled-coil quaternary structure and a
large, C-terminal fibrinogen-like domain. ANGPTL4 has three
potential N-glycosylation sites and appears to be sialylated
[4].
The native full-length ANGPTL4 can form higher-order struc-
tures via intermolecular disulfide bonds [5]. The N-terminal re-
gion of ANGPTL4 (herein designated as nANGPTL4) is respons-
ible for its assembly into either dimeric or tetrameric structures
[6], and oligomerization of ANGPTL4 is important for its func-
tion as an LPL (lipoprotein lipase) inhibitor [5–7]. The full-length
ANGPTL4 protein undergoes proteolytic processing by propro-
tein convertases at the linker region, releasing the nANGPTL4
and the monomeric C-terminal portion of ANGPTL4 (cANG-
PTL4) [6,8,9]. The cleavage of ANGPTL4 appears to be tissue-
dependent. In human, the liver secretes the cleaved nANGPTL4,
whereas adipose tissue secretes the full-length form [10]. In vitro
experiments showed that several proprotein convertases, includ-
ing PCSK3 (proprotein convertase subtilisin/kexin type3), furin
and PC5/6 (proprotein convertase 5/6), cleaved human ANG-
PTL4 via recognition of the amino acid sequence R161RKR164
[5,9]. However, the expression of these proprotein convertases in
various tissues during physiopathological conditions and whether
they are responsible for the in vivo processing of full-length
ANGPTL4 is still unknown.
Most members of the ANGPTL family are currently con-
sidered orphan ligands because information regarding their po-
tential binding partners is lacking. Notably, none of these ANG-
PTL proteins binds to TIE 1/2 tyrosine kinase receptors, sug-
gesting that they may exert distinct functions from other ANG
proteins, which play important roles in angiogenesis and hae-
mopoiesis by signalling through TIE receptors [11,12]. ANG-
PTL4 shares only ∼30 % amino acid sequence similarity with
ANGPTL3, its closest member within the family. Studies showed
that ANGPTL4 and ANGPTL3 inhibit LPL in a non-redundant
way [13]. The oligomerization of the ANGPTL4 protein determ-
ines the intrinsic ability of ANGPTL4 to inhibit LPL activity
[5,7], thus the proteolytic cleavage of ANGPTL4 by proprotein
convertases may influence this function subsidiarily [9]. Full-
length ANGPTL4 also binds to heparin sulfate proteoglycans,
but the domains for these interactions remain to be determined.
Recently, the cANGPTL4 protein was shown to interact with
integrins β1 and β5 and their cognate ECM (extracellular mat-
rix) proteins [14,15]; however, binding of ANGPTL4 to matrix
proteins did not interfere with the recognition of those matrix
proteins by their cognate integrins.
In mice, the ANGPTL4 protein is most highly expressed in
white and brown adipose tissues and to a much lesser extent in
other tissues such as ovary, heart, liver, skeletal muscle and in-
testine [3,16]. In humans, ANGPTL4 is ubiquitously expressed
at higher levels in the liver, adipose tissue, blood plasma, pla-
centa, small intestine and heart [16,17], albeit with drastic inter-
individual variations in the level of expression. Both the full-
length and truncated forms of ANGPTL4 are found in blood
plasma, but the baseline expression levels of this protein vary
greatly among different individuals [10,18]. The expression of
ANGPTL4 can be induced by numerous stimuli. Under fasting
conditions, most, but not all [19], studies indicate that the ex-
pression of ANGPTL4 is strongly up-regulated in the following
organs/tissues: adipose tissue, liver, heart, plasma and skeletal
muscle [2,20,21]; this is mediated by glucocorticoid, whose cir-
culating levels are increased during fasting [22]. In addition to
fasting, plasma ANGPTL4 levels are also increased by chronic
caloric restriction or NEFAs [non-esterified fatty acids (free fatty
acids)] [17]. The fasting- and NEFA-induced increase in AN-
GPTL4 is mediated by the nuclear hormone receptors PPARs,
which transcriptionally stimulate ANGPTL4 expression via a
functional PPAR-response element in the human and mouse AN-
GPTL4 genes [10,23,24]. Hypoxic conditions also elevate the
expression of ANGPTL4 in cadiomyocytes, adipocytes, articu-
lar chondrocytes, endothelial cells and brain [25–30]. Synthetic
agonists for PPARs raise plasma ANGPTL4 levels in humans
and mice as well [2,3,10,17,31,32]. TGFβ (transforming growth
factor β), a critical cytokine, can also stimulate ANGPTL4 ex-
pression in primary tumour cells to prime metastasis [33]. In-
terestingly, a recent finding suggested that TGFβ and PPARβ/δ
could either synergistically or antagonistically stimulate ANG-
PTL4 expression, depending on cellular contexts [23,24].
ANGPTL4 IN ENERGY HOMOEOSTASIS
Food intake
ANGPTL4 is expressed in the mouse hypothalamus, cortex and
pituitary gland, where it is subject to a number of regulatory
influences, including hypoxia [26]. Discrepant findings exist on
whether ANGPTL4 expression in the hypothalamus is induced
by fasting [20,34]; however, recent data have suggested that
ANGPTL4 is involved in regulating food intake and energy ex-
penditure [34]. Whereas central administration of ANGPTL4
lowered food intake and body weight gain and enhanced en-
ergy expenditure, deletion of ANGPTL4 had the opposite effect.
These data indicate that ANGPTL4 acts as an anorexigenic factor,
possibly via inhibition of hypothalamic AMPK (AMP-activated
protein kinase) activity [34].
Gut microbiota
ANGPTL4 has been presented as a putative factor linking the
intestinal microbiota to fat storage in adipose tissue [35]. Intro-
duction of microbiota into germ-free mice suppresses ANGPTL4
mRNA in the small intestine [35,36]; however, it is expected
that different bacterial strains differentially modulate ANGPTL4
expression. In a colonic cell line, various probiotic bacteria, in-
cluding Lactobacillus paracasei ssp. paracasei F19, caused pro-
nounced up-regulation of ANGPTL4 mRNA [37], and this up-
regulation was reproduced by factors secreted from L. paracasei
ssp. paracasei F19.
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Lipid metabolism
The demonstration of the regulation of ANGPTL4 by PPARs
provided the first clue towards a potential role in lipid metabolism.
Abundant evidence now indicates that ANGPTL4 suppresses
the clearance of circulating TAGs (triacylglycerols), which is
achieved by inhibiting LPL, the enzyme that hydrolyses TAGs in
lipoprotein particles. Accordingly, deletion of ANGPTL4 causes
lowering of circulating TAGs, whereas ANGPTL4 overexpres-
sion leads to an increase in TAGs. There is limited evidence that
ANGPTL4 also inhibits hepatic lipase, a TAG hydrolase specific-
ally expressed in liver and involved in HDL (high-density lipo-
protein) and lipoprotein remnant metabolism. ANGPTL4 inhib-
its LPL, at least partially, by promoting the conversion of active
LPL dimers into inactive LPL monomers. The primary region re-
sponsible for blocking LPL is located within 12 highly conserved
amino acids that are near the N-terminus of ANGPTL4. Mutating
three polar amino acid residues within this region abolished the
ability of ANGPTL4 to inhibit LPL [7]. Moreover, inhibition of
LPL activity by ANGPTL4 was suppressed by the LPL-anchor
and -transport protein GPIHBP1 (glycosylphosphatidylinositol-
anchored high-density lipoprotein-binding protein 1), perhaps by
stabilizing the LPL dimers [38].
Transcription of ANGPTL4 in numerous cell types is extremely
sensitive to fatty acid stimulation [17,39,40], and the induction
of ANGPTL4 by fatty acids and oral lipid overload probably
serves to protect a cell against cellular lipid overload by reducing
extracellular TAG hydrolysis and consequent fatty acid uptake.
In cardiomyocytes, this mechanism prevents lipotoxicity and ox-
idative stress [39], whereas, in macrophages, it protects against
lipid-induced macrophage activation. Failure of this mechanism
in mesenteric lymph nodes leads to excessive lipolytic release
of fatty acids from lymph chylomicrons, macrophage foam cell
formation, endoplasmic recticulum stress and marked inflamma-
tion that becomes systemic.
In addition to inhibiting LPL-dependent extracellular lipoly-
sis, ANGPTL4 also stimulates intracellular hydrolysis, as was
observed in adipocytes and myocytes [41]. Accordingly, ablation
of the ANGPTL4 gene is associated with a blunted increase in
plasma NEFA during fasting. The exact mechanism behind the
intracellular lipolytic effect of ANGPTL4 remains unclear. Con-
current inhibition and activation of extracellular and intracellular
lipolysis respectively may reduce fat storage and increase lipid
availability from adipose tissue during fasting. Interestingly, one
recent study using monozygotic twins shows that the expression
of ANGPTL4 in adipose tissue is positively correlated with the
adipose tissue hormone sensitive lipase, supporting the notion
that ANGPTL4 could promote adipose tissue lipolysis in human
[42].
Glucose homoeostasis
Adenoviral-mediated overexpression of ANGPTL4 was shown
to greatly lower circulating glucose levels and improve glucose
tolerance, which was suggested to be mediated by decreased
hepatic glucose production [32]. In contrast, whole-body ANG-
PTL4 transgenic mice of two different backgrounds exhibited
a worsening of glucose tolerance after prolonged high-fat feed-
ing [16]. Clamp studies indicated that in fasted mice, transgenic
ANGPTL4 overexpression was associated with impaired gluc-
ose utilization and insulin resistance in the periphery, but higher
insulin-mediated suppression of glucose production in the liver
[21]. No changes in plasma glucose levels were observed in
ANGPTL4− / − mice that were fed standard chow [43]. Unfortu-
nately, interpretation of the effects of deleting ANGPTL4 from
animals with high fat-induced obesity and insulin resistance is
compromised by the occurrence of a severe systemic inflammat-
ory response. Thus published data on the impact of ANGPTL4
are inconsistent.
Human genetic studies
Approximately 3 % of people of European ancestry are carriers
of an E40K variant of the ANGPTL4 gene. The E40K muta-
tion significantly impairs the ability of ANGPTL4 to inhibit LPL
by destabilizing or impairing the production of ANGPTL4 [44].
Consistent with the role of ANGPTL4 as an LPL inhibitor, car-
riers of the E40K variant exhibit decreased plasma TAG levels
[45] and, in some studies, higher HDL levels compared with
non-carriers [46]. Surprisingly, a genome-wide association study
showed that a common sequence variant at a locus near the ANG-
PTL4 gene was associated with plasma HDL but not with TAG
concentrations [47]. A more common coding variant, T266M,
was not associated with plasma TAGs or CVD (cardiovascular
disease) risk in a recent meta-analysis of five studies [44].
ANGPTL4 IN INFLAMMATION
Increased lipid uptake is typically associated with a marked stim-
ulation of inflammation- and immunity-related genes. This in-
duction can be inhibited by LPL inhibitors, indicating that the
mechanism is LPL-dependent. ANGPTL4 takes on a dampening
role with regard to the levels of inflammatory markers such as
serum amyloid A and IL-6 (interleukin-6), as shown by the elev-
ated levels of these inflammatory factors in ANGPTL4-knockout
mice that have been fed a high-saturated-fat diet. These mice
lived no longer than 25 weeks, and their fibrin exudates contained
large amounts of foam cells and various leucocytes. In addition,
epididymal adipose tissue displayed coagulation necrosis and
steatitis by both lymphocytes and granulocytes. Focal infiltrates
of neutrophils, eosinophils, macrophages and rod-shaped bac-
teria, as well as a rise in the expression of the Kupffer cell marker
CD68, were observed in the liver. The enlarged mesenteric lymph
nodes also displayed an abundance of multinucleated Touton gi-
ant cells that were formed from the fusion of lipid-filled tissue
macrophages, which is an indication of lipid lymphadenopathy.
Besides regulating inflammation, ANGPTL4 prevents the uptake
of saturated fatty acids by macrophages. ANGPTL4 is induced
by chyle, which is produced after fat intake, leading to protection
of the mesenteric lymph nodes and resident macrophages from
the pro-inflammatory effects of saturated fatty acids [48].
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The inflammatory process is an important development for the
maintenance of an optimal state of health because chronic or un-
controlled inflammation is life-threatening. Recently, ANGPTL4
was characterized as a positive acute phase protein, as its ex-
pression was stimulated in liver, heart, muscle and adipose tissue
during the acute phase response [49]. However, a direct effect of
ANGPTL4 on inflammatory pathways has yet to be demonstrated
and deserves further investigation.
ANGPTL4 IN KIDNEY DISEASE
A recent study suggested an important role for ANGPTL4 in the
kidney. It was shown that minimal change disease, a common
cause of nephrotic syndrome in children, was associated with
overproduction of ANGPTL4 in the glomerulus, which is the fil-
tering unit of the kidney [4,50]. One key morphological feature of
minimal change disease is the loss of the characteristic foot pro-
cesses of the podocyte, a specialized cell type involved in filtration
that is a site of production of ANGPTL4 in the kidney. Podocyte-
specific overexpression of ANGPTL4 in rats resulted in the devel-
opment of most of the characteristic features of this disease: large-
scale selective proteinuria, loss of glomerular basement mem-
brane charge and diffuse fusion of podocyte foot processes. Fur-
thermore, Clement et al. [4] showed an increase in hyposialylated
ANGPTL4 in a puromycin aminonucleoside-treated rat model of
podocyte injury, suggesting that sialylated and hyposialylated
glomerular ANGPTL4 might have different effects on the barrier
function of the glomerular basement membrane. Of clinical relev-
ance, the dietary sialic acid precursor N-acetyl-D-mannosamine
caused an increase in sialylation of glomerular ANGPTL4 and a
decrease in albuminuria in the same transgenic rats. Clearly, how
ANGPTL4 interacts with other pathways that are implicated in
minimal change disease needs to be investigated for the devel-
opment of effective therapies. Given the hypertriglyceridaemic
effect of ANGPTL4, it would be useful to determine if podocyte-
secreted ANGPTL4 escapes into the circulation and contributes
to the hypertriglyceridaemia component of nephrotic syndrome.
ANGPTL4 IN WOUND HEALING
ANGPTL4 plays a novel role in keratinocyte migration during
skin wound healing. Normal wound healing entails a continuum
of events that include inflammation, re-epithelialization and mat-
rix remodelling and involves a complex interplay among connect-
ive tissue formation, cellular activity and growth factor activa-
tion [51]. ECM components integrate each phase during wound
healing, communicating with cells and growth factors in a dy-
namic reciprocal manner that eventually results in proper wound
closure. Goh et al. [14,15] identified ANGPTL4 as a novel matri-
cellular protein whose expression was up-regulated by PPARβ/δ
in response to inflammation during wound healing. Full-length
ANGPTL4 and cANGPTL4 proteins, which are produced by
wound keratinocytes, co-ordinate cell–matrix communication in
several ways during the re-epithelialization phases of wound heal-
ing. ANGPTL4 independently interacts with specific matrix pro-
teins and integrins, and these proteins form a ternary complex
when present together. First, ANGPTL4 specifically interacts
with vitronectin and fibronectin in the wound bed and regulates
the availability of the local ECM by delaying the degradation
of those proteins by proteases. The delayed degradation of vit-
ronectin and fibronectin has a direct impact on integrin-mediated
signalling by altering the balance between substrate-anchored
matrix proteins and soluble matrix protein fragments. This in-
teraction does not interfere with integrin–matrix protein recog-
nition, suggesting a separate binding site (or sites) for ANG-
PTL4 to stabilize the integrin-matrix protein complex. Secondly,
ANGPTL4 specifically interacts with integrins β1 and β5 that
reside on the surface of wound keratinocytes, which activate
integrin-mediated intracellular signalling, allow for selective in-
tegrin recycling, enhance cell migration and accelerate the wound
healing process [14,15]. Numerous intracellular signalling path-
ways, including FAK (focal adhesion kinase)-, Rho GTPase and
14-3-3σ -dependent signalling cascades that emanate from in-
tegrins to modulate cell migration are activated upon activation
by ANGPTL4. ANGPTL4-deficient mice exhibit delayed wound
re-epithelialization with impaired keratinocyte migration. Given
the potential effect of ANGPTL4 on energy homoeostasis and in-
flammation, it would be useful to study the expression and effects
of ANGPTL4 on the healing of diabetic wounds.
ANGPTL4 IN CELL DIFFERENTIATION
Our understanding of the role of ANGPTL4 in cell differentiation
is in its infancy. Evidence suggested that ANGPTL4 may be in-
volved in or associated with adipose differentiation and vascular
tubule formation. During adipocyte differentiation, there is a dra-
matic early induction of the ANGPTL4 transcript, and its expres-
sion level continues to increase post-differentiation [10,16,19].
However, the in vivo role of ANGPTL4 in adipocyte matura-
tion is complicated as transgenic ANGPTL4 or knockout mice
showed normal fat mass as a result from compensatory metabolic
changes in adipose TAG metabolism [43]. The role of ANGPTL4
to stimulate endothelial cells remains controversial, with reports
supporting either a pro- or anti-angiogenic functions (see the sec-
tion on ANGPTL4 in angiogenesis and vascular permeability). A
recent study showed that PPARβ/δ mediated ANGPTL4 to regu-
late PKCs (protein kinase Cs) and AP-1 (activator protein 1) tran-
scription factor for epidermal differentiation, which is important
for the maturation of the epidermis during the remodelling phase
of wound healing [52]. ANGPTL4 stimulated the increase activa-
tion of c-Jun and JUNB, whereas it transcriptionally regulated the
expression of PKCs. The expression of epidermal differentiation
markers such as transglutaminase 1 and involucrin were induced
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by ligand activated-PPARβ/δ and ANGPTL4, which is associated
with increased AP-1 binding to the cognate promoter. Clearly,
more future investigations into the ANGPTL4-stimulated tran-
scriptional networks will be necessary for a better understanding
of the precise role of ANGPTL4 in the differentiation of other
cell types.
ANGPTL4 IN TUMORIGENESIS
Normal wound healing shares many similarities with the tumour
microenvironment, and tumour invasion has been compared with
‘wound healing gone awry.’ Consistent with this notion, ANG-
PTL4 has been identified as a prominent gene in a compact
in vivo hypoxia signature that predicts a poor outcome in multiple
tumour types [30,53]. ANGPTL4 mRNA has been found to be
up-regulated in the perinecrotic areas of many human tumours,
clear cell renal carcinomas, oral tongue squamous cell carcino-
mas and human gastric cancers [54,55]. Tissue array analysis
revealed an elevated ANGPTL4 expression in up to 40 known
human epithelial tumour types, and its expression increased as
tumours progressed from benign to metastatic states [56]. The
elevated expression of ANGPTL4 in many cancers implicated
a role of ANGPTL4 in tumour growth, and it was suggested
to play a role in metastasis through lymphovascular invasion
[57].
Numerous studies have shown that tumours frequently exhibit
elevated ROS (reactive oxygen species) and utilize a redox-based
mechanism to escape from death by anoikis. The loss of depend-
ence on integrin-mediated ECM contact for growth (or anoikis
resistance) is an essential feature of tumour cells; yet how this
resistance is acquired is a central problem in cancer biology. A
recent study by Zhu et al. [56] identified tumour-derived ANG-
PTL4 as a novel player in redox cancer biology, and they found
that it conferred anoikis resistance to tumours via autocrine adhe-
sion mimicry. Tumour-derived ANGPTL4 directly interacts with
β1 and β5 integrins, thus hijacking integrin-mediated signalling
to maintain an elevated oncogenic O2 − /H2O2 ratio. This action
stimulates the redox-mediated activation of the Src machinery
and, therefore, activates the downstream PI3K (phosphoinositide
3-kinase)/PKBα (protein kinase Bα) and ERK (extracellular-
signal-regulated kinase) signalling cascade to promote cell sur-
vival and tumour growth. Of note, the suppression of ANGPTL4
by RNAi (RNA interference) modulates intracellular ROS gener-
ation to attenuate tumour growth that is associated with enhanced
apoptosis in vitro and in vivo. Intriguingly, treatment with a mAb
(monoclonal antibody; 11F6C4) against human cANGPTL4 sig-
nificantly retards melanoma growth in a mouse model, reprodu-
cing the RNAi effects. Unlike another reported anti-ANGPTL4
antibody (14D12), which targets the N-terminus of the mouse
ANGPTL4 protein [58], 11F6C4 targets an epitope that resides
within the C-terminus of human ANGPTL4, and it does not af-
fect the mitochondrial activities and glucose regulations of this
protein (P. Zhu, M.J. Tan, H.C. Chong and N.S. Tan, unpublished
work). Indeed, ANGPTL4 has been found to contribute to anoi-
kis resistance in hepatoma cells [59]. When grown in a detached
state, hepatoma cells form a synoikis-like multicellular aggregate
that is resistant to inducers of apoptosis. Additionally, ANGPTL4
knockdown enhanced cell apoptosis and sensitized tumour cells
to drug treatment, confirming that ANGPTL4 played a key role
in anoikis resistance. These exciting findings suggest that antic-
ancer strategies that focus on redox-based apoptosis induction in
tumours may be clinically viable.
ANGPTL4 IN ANGIOGENESIS AND
VASCULAR PERMEABILITY
Communication between tumour cells and the endothelium that
encourages angiogenesis and vasculature permeability is crucial
for the continued growth and metastasis of the tumour respect-
ively. Angiogenesis, i.e. the formation of new blood vessels that
originate from the existing vascular system, helps the tumour
grow by feeding the cancer cells with essential nutrients and
oxygen. Neovascularization also influences the dissemination of
cancer cells throughout the entire body and eventually leads to
metastasis. The vascularization level of a solid tumour is thought
to be an excellent indicator of its metastatic potential. Despite
major advances in the field of tumour angiogenesis, relatively
little attention has been paid to the permeability of blood vessels
in tumours. The leakiness of tumour vessels has been well docu-
mented in experimental tumour models and in human cancer, but
the mechanism is poorly understood. Tumour metastasis depends
on a state of increased vasculature leakiness and on the critical
steps of intravasation and extravasation, which involve the direc-
tional migration of tumour cells across the disrupted endothelium.
Tumour-induced angiogenesis is mainly sustained by the pro-
duction and secretion of angiogenic factors, e.g. vascular en-
dothelial growth factor [60] and ANGs, which originate from
tumour and stromal cells [61]. Given the similarity between
ANGPTL and the ANG proteins, the potential involvement
of ANGPTL4 in angiogenesis and vascular permeability has
been a subject of much study. To date, the role of ANGPTL4
in angiogenesis and vascular leakiness remains controversial,
and it is more likely that ANGPTL4 functions as a ‘gate-
keeper’ that regulates vascular integrity in a context-dependent
manner [62]. Early studies proposed an anti-angiogenic role of
ANGPTL4; therefore, it could prevent metastasis by inhibiting
vascular leakiness [63]. The ECM-bound, but not the soluble,
form of ANGPTL4 inhibits endothelial cell adhesion, migra-
tion and sprouting [64]. Furthermore, ANGPTL4 was reported
to prevent metastasis through inhibition of angiogenesis, tumour
cell motility and invasion [64,65]. However, other reports have
proposed that ANGPTL4 is pro-angiogenic and pro-metastatic.
ANGPTL4 was found to significantly promote in vitro sprouting
of vascular endothelial cells, and this finding was supported by
work on a conventional renal cell carcinoma that proposed ANG-
PTL4 as a pro-angiogenic factor during ischaemia [55]. Notably,
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Figure 1 Multiple roles of ANGPTL4 in energy homoeostasis
Expression of ANGPTL4 is increased by various conditions and factors. ANGPTL4 is a secreted protein that can be
proteolytically cleaved to release the N-terminal coiled-coil fragment (nANGPTL4) and the C-terminal fibrinogen-like fragment
(cANGPTL4). ANGPTL4 is a central player in many aspects of energy homoeostasis. Studies have shown that nANGPTL4
binds and inhibits LPL to regulate lipolysis, glucose homoeostasis and fat storage as well as inflammation. ANGPTL4 has
been implicated to modulate AMPK activity to regulate food intake and energy expenditure. Hyposialylated ANGPTL4
has also been shown to be associated with minimal change disease, which is a common cause of nephritic syndrome.
ANGPTL4 has been identified as one of the genes that can pre-
dict breast cancer to lung metastasis with the greatest frequency
[66], and further studies indicated that TGFβ primes breast tu-
mours for the seeding of lung metastasis through ANGPTL4
by modulating endothelial integrity to mediate lung metastasis
seeding [59]. TGFβ-induced ANGPTL4 enhances the retention
of cancer cells in the lungs, disrupts vascular endothelial cell–cell
junctions, increases the permeability of the lung capillaries, and
facilitates the trans-endothelial passage of tumour cells, thus pro-
moting the vital steps of metastasis [33]. Until recently, there has
been no further mechanistic understanding of ANGPTL4 on vas-
cular leakiness. A recent study by Huang et al. [67] has provided
new insight into the precise role of ANGPTL4 in this process. The
report demonstrated that tumour-derived cANGPTL4 instigated
the disruption of endothelial continuity by directly interacting
with three novel binding partners: integrin α5β1, VE-cadherin
(vascular endothelial cadherin) and claudin-5, in a temporally se-
quential manner, thus facilitating metastasis. Indeed, the authors
[67] showed that tumour cells and mice that were deficient in
ANGPTL4 had reduced vascular permeability; furthermore, the
mice had attenuated lung metastasis.
In all, growing evidence has led us to evaluate the potential of
targeting ANGPTL4 as a therapeutic strategy in treatments that
are aimed at various diseases such as diabetes, cancer and other
vascular pathologies.
CONCLUSIONS AND PERSPECTIVES
It has been more than a decade since the first identification of
ANGPTL4, and now this protein is emerging as a central player
in many aspects of energy homoeostasis (Figure 1). Recent find-
ings have implicated ANGPTL4 in other non-metabolic, physio-
logical and pathological situations, such as wound healing, on-
cogenesis and angiogenesis (Figure 2). Although these recent
discoveries have generated renewed excitement and provided
tremendous insight into the diverse roles of ANGPTL4, many
questions remain unaddressed. While the role of ANGPTL4 in
lipid metabolism can be directly or indirectly attributed to its
inhibitory interaction with LPL, this mechanism is inadequate
to explain other facets such as intracellular lipolysis. The dis-
parate role of ANGPTL4 in glucose metabolism also remains to
be clarified. Central to this question is the mechanism for the
differential expression and cleavage of ANGPTL4, which gen-
erates the full-length ANGPTL4, nANGPTL4 and cANGPTL4
that are observed in various tissues. Thus far, the findings sug-
gest that the post-translational processing of the ANGPTL4 may
be cell/tissue context-specific and pathologically/physiologically
dependent events. In addition to its role as an adipokine,
ANGPTL4 has also been recognized as a novel matricellular pro-
tein, which affects cell–matrix communication and is important
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Figure 2 Roles of ANGPTL4 in non-metabolic physiopathological situations
(a) ANGPTL4 plays important roles in wound repair. ANGPTL4 produced by wound keratinocytes, co-ordinates cell–matrix
communication to modulate keratinocyte migration during wound healing. ANGPTL4 also regulates PKCs and AP-1 for
epidermal differentiation, facilitating the maturation of the epidermis during the remodelling phase of wound healing.
(b) Cancer-derived cANGPTL4 plays multiple roles in tumour progression. In an autocrine manner, cANGPTL4 sustains
cancer cell survival and promotes tumour growth. Cancer-derived cANGPTL4 can also act in a paracrine fashion on
endothelial cells to promote angiogenesis and to increase vascular leakiness, thus promoting metastasis.
for wound healing, tumorigenesis and vascular integrity. Many
early studies using adenovirus-mediated or other methodologies
to overexpress ANGPTL4 in cells failed to clarify which protein
forms were used in those experiments. Given recent findings, in-
cluding our study showing that full-length and truncated forms
of ANGPTL4 might exert a distinct array of roles in different
contexts [56], all of the studies mentioned in the sections of this
review need to be revisited. The discovery that ANGPTL4 can
associate with matrix proteins and integrins to modulate integrin-
mediated signalling is a pivotal step towards a better understand-
ing of ANGPTL4-mediated signalling. However, the characteriz-
ation of the full repertoire of ANGPTL4-interacting partners and
the intracellular signalling cascade of these interactions awaits
more extensive study. Taken together, the research findings from
the last decade have laid the foundation for a better mechanistic
understanding of and new scientific discoveries on the diverse
roles of ANGPTL4.
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